Nkarta - Allogeneic CAR Natural Killer (NK) Cell Therapy

Health Professional Radio - Podcast

Content provided by Health Professional Radio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Health Professional Radio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

3+ y ago 10:08

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on October 25, 2022 13:32 (1+ y ago). Last successful fetch was on May 03, 2022 16:48 (2y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Paul Hastings, CEO of Nkarta Therapeutics discusses results from their NKX101 study, an allogeneic CAR Natural Killer (NK) cell therapy, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS). Paul is the President and Chief Executive Officer of Nkarta, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer. After beginning his career in sales and marketing at Hoffman-LaRoche, he has led more than a dozen biopharma companies as CEO, President or Director. He currently serves as Vice Chair and member of the Executive Committee of BIO.

683 episodes

#Fitness #Vertical Internet Media 454422 #Health and Well-Being #Health Professional Radio #On Covid19